Cardiac disease (history of and/or active disease) that would preclude the use of the drugs included in the treatment regimens; this includes but is not confined to:\r\n* Active cardiac disease\r\n** Angina pectoris that requires the current use of anti-anginal medication;\r\n** Ventricular arrhythmias except for benign premature ventricular contractions;\r\n** Supraventricular and nodal arrhythmias requiring a pacemaker or not controlled with medication;\r\n** Conduction abnormality requiring a pacemaker;\r\n** Valvular disease with documented compromise in cardiac function; or\r\n** Symptomatic pericarditis\r\n* History of cardiac disease\r\n** Myocardial infarction documented by elevated cardiac enzymes or persistent regional wall abnormalities on assessment of left ventricle (LV) function;\r\n** History of documented congestive heart failure (CHF); or\r\n** Documented cardiomyopathy
Active cardiac disease: angina pectoris that requires the use of anti-anginal medication; ventricular arrhythmias except for benign premature ventricular contractions; supraventricular and nodal arrhythmias requiring a pacemaker or not controlled with medication; conduction abnormality requiring a pacemaker; valvular disease with documented compromise in cardiac function; or symptomatic pericarditis.
Cardiac disease (history of and/or active disease) that would preclude the use of any of the drugs included in the treatment regimen; this includes but is not confined to: \r\n* Active cardiac diseases including: \r\n** Symptomatic angina pectoris within the past 180 days that required the initiation of or increase in anti-anginal medication or other intervention\r\n** Ventricular arrhythmias except for benign premature ventricular contractions\r\n** Supraventricular and nodal arrhythmias requiring a pacemaker or not controlled with medication\r\n** Conduction abnormality requiring a pacemaker\r\n** Valvular disease with documented compromise in cardiac function\r\n** Symptomatic pericarditis \r\n* History of cardiac disease:\r\n** Myocardial infarction documented by elevated cardiac enzymes or persistent regional wall abnormalities on assessment of left ventricular (LV) function\r\n** History of documented congestive heart failure (CHF) \r\n** Documented cardiomyopathy
Cardiac disease that would preclude administration of the drugs included in the study treatment regimen including, but not limited to:\r\n* Angina pectoris that requires the current use of anti-anginal medication\r\n* Ventricular arrhythmias except for benign premature ventricular contractions\r\n* Supraventricular and nodal arrhythmias requiring a pacemaker or not controlled with medication\r\n* Conduction abnormality requiring a pacemaker\r\n* Valvular disease with documented compromise in cardiac function; and symptomatic pericarditis
Patient has active cardiac disease including any of the following: \r\n* Corrected QT (QTc) > 500 msec on screening electrocardiogram (ECG) (using the QTc Fridericia [F] formula)\r\n* Angina pectoris that requires the use of anti-anginal medication\r\n* Ventricular arrhythmias except for benign premature ventricular contractions\r\n* Supraventricular and nodal arrhythmias requiring a pacemaker or not controlled with medication\r\n* Conduction abnormality requiring a pacemaker\r\n* Valvular disease with document compromise in cardiac function\r\n* Symptomatic pericarditis
Active cardiac disease: symptomatic angina pectoris within the past 90 days that required the initiation of or increase in anti-anginal medication or other intervention; ventricular arrhythmias except for benign premature ventricular contractions; supraventricular and nodal arrhythmias requiring a pacemaker or not controlled with medication; conduction abnormality requiring a pacemaker; valvular disease with documented compromise in cardiac function; and symptomatic pericarditis
Patient has active cardiac disease including any of the following:\r\n* Left ventricular ejection fraction (LVEF) < 50% as determined by multiple gated acquisition (MUGA) scan or echocardiogram (ECHO)\r\n* Corrected QT (QTc) interval > 480 msec on screening electrocardiogram (ECG) (using the QTc Fridericia [F] formula)\r\n* Angina pectoris that requires the use of anti-anginal medication\r\n* Ventricular arrhythmias except for benign premature ventricular contractions\r\n* Supraventricular and nodal arrhythmias requiring a pacemaker or not controlled with medication\r\n* Conduction abnormality requiring a pacemaker\r\n* Valvular disease with document compromise in cardiac function\r\n* Symptomatic pericarditis
Patient has active cardiac disease including any of the following:\r\n* Left ventricular ejection fraction (LVEF) < 50% as determined by Multiple Gated acquisition (MUGA) scan or echocardiogram (ECHO)\r\n* Corrected QT (QTc) > 480 msec on screening electrocardiogram (ECG) (using the QT with Fridericia’s Correction [QTcF])\r\n* Angina pectoris that requires the use of anti-anginal medication\r\n* Ventricular arrhythmias except for benign premature ventricular contractions\r\n* Supraventricular and nodal arrhythmias requiring a pacemaker or not controlled with medication\r\n* Conduction abnormality requiring a pacemaker\r\n* Valvular disease with document compromise in cardiac function\r\n* Symptomatic pericarditis
Cardiac disease (history of and/or active disease) that would preclude the use of the drugs included in the treatment regimens; this includes but is not confined to:\r\n* Active cardiac disease\r\n** Angina pectoris that requires the current use of anti-anginal medication;\r\n** Ventricular arrhythmias except for benign premature ventricular contractions;\r\n** Supraventricular and nodal arrhythmias requiring a pacemaker or not controlled with medication;\r\n** Conduction abnormality requiring a pacemaker;\r\n** Valvular disease with documented compromise in cardiac function; or\r\n** Symptomatic pericarditis\r\n* History of cardiac disease\r\n** Prior myocardial infarction documented by elevated cardiac enzymes or persistent regional wall abnormalities on assessment of left ventricular (LV) function;\r\n** History of documented congestive heart failure (CHF) defined as symptomatic heart failure with an LVEF < 40%; or\r\n** Documented cardiomyopathy
Participant has active cardiac disease including any of the following:\r\n* Angina pectoris that requires the use of anti-anginal medications\r\n* Ventricular arrhythmias except for benign premature ventricular contractions\r\n* Supraventricular and nodal arrhythmias requiring a pacemaker or not controlled with medication\r\n* Conduction abnormality requiring a pacemaker\r\n* Valvular disease with document compromise in cardiac function\r\n* Symptomatic pericarditis
Patient has a history of cardiac dysfunction or disease including any of the following:\r\n* Myocardial infarction within the last 6 months, documented by persistent elevated cardiac enzymes or persistent regional wall abnormalities on assessment of left ventricular ejection fraction (LVEF) function\r\n* History of documented congestive heart failure (New York Heart Association functional classification III-IV) or documented cardiomyopathy\r\n* Corrected QT (QTc) interval > 470 msec on screening electrocardiogram (EKG) (using the QTc-Fridericia [QTcF] formula)\r\n* Angina pectoris that requires the use of anti-anginal medication\r\n* Ventricular arrhythmias except for benign premature ventricular contractions\r\n* Left ventricular ejection fraction (LVEF) < 50% as determined by multiple gated acquisition (MUGA) scan or echocardiogram (ECHO)\r\n* Supraventricular and nodal arrhythmias requiring a pacemaker or not controlled with medications\r\n* Conduction abnormality requiring a pacemaker\r\n* Valvular disease with documented compromise in cardiac function\r\n* Known history of QT/QTc prolongation or torsades de pointes (TdP); patients who are currently receiving treatment with medication with a known risk to prolong the QT interval or inducing torsades de pointes and the treatment cannot either be discontinued or switched to a different medication prior to starting study drugs\r\n* Symptomatic pericarditis\r\n* ST depression or elevation of >= 1.5 mm in 2 or more leads
Subject has active cardiac disease or a history of cardiac dysfunction including any of the following:\r\n* Unstable angina pectoris within 6 months prior to study entry\r\n* Symptomatic peritonitis\r\n* Documented myocardial infarction within 6 months prior to study entry\r\n* History of documented congestive heart failure (New York Heart Association functional classification III-IV)\r\n* Documented cardiomyopathy\r\n* Subject has a left ventricular ejection fraction (LVEF) < 50% as determined by multiple gated acquisition (MUGA) scan or echocardiogram (ECHO)\r\n* Subject has any of the following cardiac conduction abnormalities\r\n* Ventricular arrhythmias except for benign premature ventricular contractions\r\n* Supraventricular and nodal arrhythmias requiring a pacemaker or not controlled with medicine\r\n* Conduction abnormality requiring a pacemaker\r\n* Other cardiac arrhythmia not controlled with medication
Cardiac disease (history of and/or active disease) that would preclude the use of the drugs included in the treatment regimens; this includes but is not confined to:\r\n* Active cardiac disease:\r\n** Angina pectoris that requires the use of anti-anginal medication;\r\n** Ventricular arrhythmias except for benign premature ventricular contractions;\r\n** Supraventricular and nodal arrhythmias requiring a pacemaker or not controlled with medication;\r\n** Conduction abnormality requiring a pacemaker;\r\n** Valvular disease with documented compromise in cardiac function; and\r\n** Symptomatic pericarditis\r\n*History of cardiac disease:\r\n** Myocardial infarction documented by elevated cardiac enzymes or persistent regional wall abnormalities on assessment of left ventricular (LV) function;\r\n** History of documented congestive heart failure (CHF); and\r\n** Documented cardiomyopathy
Patient has active cardiac disease including any of the following: \r\n* Left ventricular ejection fraction (LVEF) < 50% as determined by multiple gated acquisition (MUGA) scan or echocardiogram (ECHO) \r\n* Corrected QT (QTc) > 480 msec on screening electrocardiogram (ECG) (using the Fridericia QT correction [QTcF] formula)\r\n* Angina pectoris that requires the use of anti-anginal medication\r\n* Ventricular arrhythmias except for benign premature ventricular contractions\r\n* Supraventricular and nodal arrhythmias requiring a pacemaker or not controlled with medication\r\n* Conduction abnormality requiring a pacemaker\r\n* Valvular disease with document compromise in cardiac function \r\n* Symptomatic pericarditis
Patient has active cardiac disease or cardiac dysfunction including any of the following:\r\n* Left ventricular ejection fraction (LVEF) 50% as determined by multiple gated acquisition (MUGA) scan or echocardiogram (ECHO)\r\n* Corrected QT interval (QTc) > 480 msec on screening electrocardiogram (ECG) (using the QTc Fridericia's [QTcF] formula)\r\n* Angina pectoris that requires the use of anti-anginal medications\r\n* Ventricular arrhythmias except for benign premature ventricular contractions\r\n* Supraventricular and nodal arrhythmias requiring a pacemaker or not controlled with medication\r\n* Conduction abnormality requiring a pacemaker\r\n* Valvular disease with documented compromise in cardiac function\r\n* Symptomatic pericarditis\r\n* Myocardial infarction within the last 6 months, documented by persistent elevated cardiac enzymes or persistent regional wall motion abnormalities on assessment of left ventricular ejection fraction function\r\n* History of documented congestive heart failure (New York Heart Association functional classification III-IV)\r\n* Documented cardiomyopathy\r\n* Congenital long QT syndrome
Patient has known active cardiac disease including any of the following:\r\n* Left ventricular ejection fraction (LVEF) < 50% as determined by multiple gated acquisition (MUGA) scan or echocardiogram (ECHO) \r\n* Corrected QT interval (QTc) > 480 msec on screening echocardiogram (ECG) (using the QT interval corrected by the Fridericia formula [QTcF])\r\n* Angina pectoris that requires the use of anti-anginal medication\r\n* Ventricular arrhythmias except for benign premature ventricular contractions\r\n* Supraventricular and nodal arrhythmias requiring a pacemaker or not controlled with medication\r\n* Conduction abnormality requiring a pacemaker\r\n* Valvular disease with document compromise in cardiac function \r\n* Symptomatic pericarditis
Patients with active cardiac disease including any of the following:\r\n* Left ventricular ejection fraction < 50% as determined by multi gated acquisition scan (MUGA) scan or echocardiogram\r\n* Corrected QT (QTc) > 480 msec on screening ECG (using the corrected QT interval using the Fridericia's [QTcF] formula)\r\n* Active angina pectoris\r\n* Ventricular arrhythmias except for benign premature ventricular contractions\r\n* Supraventricular or nodal arrhythmias or any conduction abnormality requiring a pacemaker or automatic implantable cardioverter defibrillator (AICD)\r\n* Valvular disease with documented compromise in cardiac function\r\n* Symptomatic pericarditis\r\n* Myocardial infarction within the past 6 months\r\n* Congestive heart failure (New York Heart Association [NYHA] functional classification III-IV)
Patient has active cardiac disease including any of the following: \r\n* History of clinically significant heart failure (previously assessed) with a left ventricular ejection fraction (LVEF) of < 50% as determined by multiple grated acquisition (MUGA) scan or echocardiogram (ECHO) \r\n* Corrected QT (QTc) > 480 msec on screening electrocardiogram (ECG) (using the Fridericia QT correction [QTcF] formula)\r\n* Angina pectoris that requires the use of anti-anginal medication\r\n* Ventricular arrhythmias except for benign premature ventricular contractions\r\n* Supraventricular and nodal arrhythmias requiring a pacemaker or not controlled with medication\r\n* Conduction abnormality requiring a pacemaker\r\n* Valvular disease with document compromise in cardiac function \r\n* Symptomatic pericarditis
Active cardiac disease including any of the following:\r\n* Angina pectoris that requires the use of anti-anginal medication\r\n* Ventricular arrhythmias except for benign premature ventricular contractions\r\n* Supraventricular and nodal arrhythmias requiring a pacemaker or not controlled with medication\r\n* Conduction abnormality requiring a pacemaker\r\n* Valvular disease with documented compromise in cardiac function\r\n* Symptomatic pericarditis
Patient has active cardiac disease including any of the following:\r\n* Left ventricular ejection fraction (LVEF) < 50% as determined by multiple gated acquisition (MUGA) scan or echocardiogram (ECHO)\r\n* QTc > 450 msec on screening electrocardiogram (ECG) (using the QTcF formula)\r\n* Angina pectoris that requires the use of anti-anginal medication\r\n* Ventricular arrhythmias except for benign premature ventricular contractions\r\n* Supraventricular and nodal arrhythmias requiring a pacemaker or not controlled with medication\r\n* Conduction abnormality requiring a pacemaker\r\n* Valvular disease with document compromise in cardiac function\r\n* Symptomatic pericarditis
Active cardiac disease including any of the following:\r\n* History of left ventricular ejection fraction (LVEF) < 50% as determined by multiple gated acquisition (MUGA) scan or echocardiogram (ECHO)\r\n* Frederica corrected QT interval (QTcF) > 450 msec on screening electrocardiogram (ECG)\r\n* Angina pectoris that requires the use of anti-anginal medication\r\n* History of ventricular arrhythmias except for benign premature ventricular contractions\r\n* Supraventricular and nodal arrhythmias requiring a pacemaker or not controlled with medication\r\n* Conduction abnormality requiring a pacemaker\r\n* Valvular disease with documented compromise in cardiac function\r\n* Symptomatic pericarditis